Hippocampal Network Function in Epilepsy
Launched by UNIVERSITY OF CHICAGO · Jul 24, 2024
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The purpose of this pilot study is to investigate hippocampal network dysfunction associated with mesial temporal lobe epilepsy (MTLE) and to examine whether network-targeted transcranial magnetic stimulation (TMS) can affect hippocampal connectivity, cognitive performance, and epileptic activity observed in adult subjects with MTLE.
Subjects will be recruited through the University of Chicago Medicine Comprehensive Epilepsy Center and other local epilepsy centers. Subjects will complete up to 8 experimental sessions (1 baseline experiment/assessment, up to 5 TMS sessions, up to 2 post-tre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of (pharmacoresistant) MTLE
- • Age 18+ years old
- • Native English speakers
- • Normal or corrected-to-normal near and far vision
- • Stable antiepileptic drugs (AED) regimen (unchanged for at least 1 month)
- Exclusion criteria:
- • Diagnosis of neurological illness other than MTLE
- • Taking drugs that impair cognition other than anticonvulsive medication for the treatment of MTLE (e.g., antipsychotics or psychostimulants).
- • Children under the age of 18 years
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Joel Voss, PhD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported